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Abstract
Introduction and objectives: Frailty has been studied extensively in elderly population as a predictor and prognostic
marker for morbidity and mortality. Frailty is being increasingly recognized as a distinct pathophysiological condition
which plays a major role in outcomes of various disease states including heart failure. Our aim was to study the
prevalence of frailty in heart failure and see its prognostic signiﬁcance in such patients.
Methods: This was a prospective study conducted in an out-patient HF clinic. All consecutive patients with HF, ≥25
years age, with LVEF<40% were included. All patients were asked a simple frailty questionnaire. Hand-dynamometer
was used to assess handgrip strength in kilograms and were classiﬁed as frail, pre-frail or non-frail. The primary end
point was cardiovascular mortality and hospitalization, and secondary end-point was composite of all cause mortality,
hospitalization, device implantation and documented arrythmia.
Results: 210 patients were studied for clinical outcomes.Mean age was 60.59 ± 11.55 years with 15% patients aged less
than 50 years. Mean LVEF was 30.24 ± 6.8%. Handgrip strength was poor in the frail vs non/pre-frail patients (p ¼ 0.001)
with a strength >16.95 kg having sensitivity of 72% and speciﬁcity of 63% for the prediction of survival. Frailty was an
independent predictor of mortality with higher mortality and re-hospitalization in frail population (p ¼ 0.001). Hazard
for mortality or hospitalization was 4.7 fold in frail population.
Conclusion: Frailty is associated with a signiﬁcant morbidity and mortality in heart failure. A simple bedside handdynamometer may aid as a frailty screening tool in these patients and help in planning treatment strategies.
Keywords: Heart failure, Frailty, Handgrip measurement

1. Background

P

resence of frailty in chronic heart failure is an
important prognostic marker in addition to
the cardiac hemodynamic status per se. Fried
et al. [1] deﬁned frailty when three out of
following criteria were met- 1) Unintentional
weight loss, 2) self-reported exhaustion, 3) weakness (grip strength), 4) slow walking speed, and 5)

low physical activity. All these criteria were
phenotypic components of the syndrome of
frailty. Further, the search for a conceptual deﬁnition of frailty has seen various parameters being
included [2]. Frailty is a pathologic state characterized by multiorgan involvement resulting in
poor quality of life and morbidity. Frailty in heart
failure has been reported to be present in
36.2e52.8% patients owing to disturbances in
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neurohormonal, musculoskeletal, metabolic and
immunological systems in the body [3,4]. It has
been widely noted that frailty is associated with
higher mortality rates, cognitive decline,
disability, falls, social detachment and behavioral
changes [5]. Frail individuals are also at higher
risk of development of heart failure [2]. Aili SR
et al. studied the frailty and cognition together as
predictors of mortality in patients with heart
failure referred to their transplant unit. They
found that physical frailty predicted early mortality and addition of cognitive assessment further
identiﬁed patients who had a poor prognosis [6].
As the heart failure advances, it causes a decline
in oxidative capacity of skeletal muscle along with
reduced capillary density and cross sectional area
of myocardial ﬁbre [7,8].
The early identiﬁcation of Frailty in heart failure
provides an opportunity for correction of reversible
factors like nutrition, physical strengthening,
neuromuscular coordination, mobility, endurance
and balance [9]. As compared to the western population there are considerable differences in the
body habitus, muscle mass, endurance, dietary
patterns and nutritional status in Indian population.
There is no frailty measurement score or calculator
which is validated for heart failure patients. Measurement of frailty in heart failure may help identify
and correct reversible factors thus improving quality of life and clinical outcomes especially in a
developing country like India. These observational
studies have mostly been carried out in elderly
population with CHF, however, it is noted to be
prevalent in the younger age groups also [10e12].
The data regarding the morbidity and mortality in
the real world outpatient setting in heart failure
population has been lacking. We aim to study the
prevalence of frailty in heart failure and see its
prognostic signiﬁcance in such patients.

2. Material and methods
This study design is prospective and non-randomized, done at the Department of cardiology outpatient clinic with enrolment of patients from Jan
2019eDec 2019. All consecutive patients undergoing
management of chronic heart failure were enrolled.
We hypothesized that presence of frailty is an independent marker of morbidity and mortality in
chronic heart failure patients. Our aim was to study
the prevalence of frailty in chronic heart failure
patients and to assess the prognostic relevance of
frailty in relation to one-year outcomes. The study

Abbrevations
ACE-I
ARB
BNP
BMI
HFrEF
HF
IHD
LVEF
TSH

Angiotensin converting enzyme inhibitor
Angiotensin receptor blocker
Brain natriuretic peptide
Body mass index
Heart failure with reduced ejection fraction
Heart failure
Ischemic heart disease
Left ventricular ejection fraction
Thyroid stimulating hormone

design was approved by the institute ethics clearance board. Informed consent was taken from all
patients before enrollment. All consecutive patients
with age >25 years, and left ventricular ejection
fraction <40% with a diagnosis of chronic heart
failure on medical therapy for at least 6 months
were included. The exclusion criteria were: 1) patients who have a received a cardiac resynchronization therapy device, 2) patients on maintenance
hemodialysis, 3) non-ambulatory patients due to
other causes like neurological/orthopaedic diseases,
4) life expectancy less than one year due to comorbid conditions. The ﬂow chart of the study is given
in Fig. 1.
2.1. Procedure
All patients enrolled were asked a questionnaire
as given by Fried phenotypic deﬁnition of Frailty [1].
The patients were classiﬁed as per the phenotypes.
The handgrip was measured with a digital hand
dynamometer and a minimum of two attempts were
taken. The best attempt out of two will be counted
for score calculation. A patient is labelled as frail
if  3/5 criteria are met, 1e2 are classiﬁed as pre frail
and score 0 were non-frail.
This frailty calculator was used in our population
as the study population included patients from
different age groups and educational backgrounds.
Additionally, we wanted to test a method which is
easy to use and understand for the patient, nursing
and paramedical staff. This method offers a wider
application to patients who are residents of peripheral locations where availability of advanced
health services might not be possible. Further,
frailty measurement may act as a screening tool to
identify patients who might beneﬁt from certain
interventions and if needed referral to higher centers for management. One of the drawbacks of using
this method is that heart failure patients may have
different clinical condition during different times in
a year. For example, during winter heart failure may
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Fig. 1. Impact of frailty on patients with heart failure. Flow-chart of the study.

worsen, during summer renal parameters may
change due to change in ﬂuid intake. Therefore this
may make changes to the frailty measurement and
assessment. However, still the identiﬁcation of parameters early may allow intervention at an appropriate time.
2.2. Nutritional assessment
The nutritional assessment was done at baseline
at the time of enrolment by the mini nutritional
assessment score.A) Anthropometric: calculation of
body mass index B)biochemical evaluation, C) dietary history: simple questionnaire-a)frequency of
meals in last 2 days out of 3 meals, b) snacks in
between, c) appetite, d) approximate ﬂuid intake per
day.

was analysed. Further, on follow-up visits all the
patients were asked for admissions at other hospitals or need for medication from other clinics.
Mortality was conﬁrmed from hospital records or
telephonic calls if the patient did not report till 4
weeks after the appointment date. In case we were
unable to connect to the family, we contacted the
family through mail or physical visit to the house of
the patient by one of hospital staff/through some
other patient/relative/village head/head of the locality for all patients from the state of Punjab. Patients from other states whom we were unable to
reach by all the above measures were excluded from
the analysis.
During the followup visits the aim of heart failure
clinic was to titrate the guideline directed medical
therapy to maximally tolerated doses and all patients were educated for drug compliance.

2.3. Followup
2.4. Study-endpoints
All the patients were assessed and examined
during the followup visits in out-patient clinics or
during the hospital admissions. Various events were
recorded from the outpatient visit records, electronic records, investigations and assessment
sheets. If some patient was admitted that record ﬁle

The primary end-points were all-cause mortality
and heart failure-related hospitalization. The secondary end-points were composite of 1) All-cause
mortality and HF related hospitalization, 2) Device
implantation (pacemaker/intra-cardiac deﬁbrillator
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or cardiac re-synchronization),3) Documented
arrhythmia, 4) CVA (cerebrovascular accident). All
patients were followed till one year for clinical
endpoints.
2.5. Statistics
All data was handled with care to maintain patient
conﬁdentiality. Records are maintained in both
computer and paper formats. Descriptive summaries are presented as frequencies and percentages for categorical data, and as means and
standard deviations for continuous variables. Survival analysis was done with Kaplan Meir curves
and log rank test was used to calculate p value. All
statistical analyses were performed using the SPSS
statistical software package (release 20.0, SPSS Inc.;
Chicago, Ill).

3. Results
This study included all patients with a diagnosis of
heart failure at a tertiary care center in North India
(Fig. 1). We screened 346 patients for inclusion in
the study. 19 patients were lost to follow up and data
was not available for analysis. 117 patients were
excluded from the study analysis (27 patients
refused to participate, 23 had other co-morbid conditions like advanced neurological diseases who
were not ambulatory, 22 had malignancies with
poor prognosis, 19 were on hemodialysis, 19 underwent cardiac resynchronization device, 6 had
unnatural cause of death (road side accidents, anake
bite, and gunshot injury), 2 patients shifted to nonallopathic medications and refused followup). A
total of 210 patients were studied for the clinical
end-points. The baseline characteristics are given in
(Table 1a). The mean age of the study population

Table 1. a) Baseline characteristics of patients (ACE-I/ARB-Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker, BNP-Brain
natriuretic peptide,BMI-Body mass index, IHD-Ischemic heart disease, TSH-Thyroid stimulating hormone). b) Baseline characteristics according to
presence of frailty.
a)
N ¼ 210
Age(years)Mean þ SD
Sex(M/F)
BMI(Kg/m2)
Diabetes(n,%)
Hypertension (n,%)
IHD(n,%)
Smoker
LVEF(%)Mean ± SD
Creatinine(mg/dl)Mean ± SD
Beta blockers(n, %)
Diuretics(n, %)
ACE I/ARB(n, %)
Hemoglobin(gm/dl) Mean þ SD
TSH Mean þ SD
BNP Mean þ SD

60.59 ± 11.55
1.61:1
24.1 ± 1.83
72 (31.4)
96 (41.9)
102 (44.5)
54 (23.6)
30.24 ± 6.8
1.30 ± 1.14
88(41.9)
196 (93.3)
157 (74.8)
12.22 ± 1.88
4.35 ± 3.08
915.43 ± 889.19

b)
Frailty type

Age group
<50 (years(%))
50-75 (years(%))
>75 (years(%))
LVEF(%)
SEX
Female(n,%)
Male(n,%)
DRUGSBeta blockers(n,%)
ACE I/ARB (n,%)
Diuretics(n,%)
BMI(Kg/m)
Creatinine(mg/dl)
Hemoglobin(gm/dl)

p-value

Non-Frail (n ¼ 6)

Pre-Frail(n ¼ 111)

Frail(n ¼ 93)

2 (6.3)
4 (2.5)
0 (0)
33.7 ± 7.4

21 (65.6)
87 (55.4)
3 (14.3)
30.10 ± 7.6

9 (28.1)
66 (42)
18 (85.7)
30.19 ± 5.7

0 (0)
6 (4.2)

37 (54.4)
74 (52.1)

31 (45.6)
62 (43.7)

0.228

4 (4.5)
6 (3.8)
6 (3.1)
24.8 ± 0.85
1.01 ± 0.17
13.05 ± 1.40

52 (59.1)
93 (59.2)
102 (52)
24.02 ± 1.7
1.07 ± 0.61
12.5 ± 1.6

32 (36.4)
58 (36.9)
88 (44.9)
24.2 ± 1.99
1.59 ± 1.52
11.81 ± 2.1

0.092
0.001
0.592
0.413
0.005
0.017

0.001

0.444

Table 2. Study endpoints according to the frailty. (*p value < 0.05). (CVA- Cerebrovascular accident).
Endpoint

Non-frail(n ¼ 6)

Pre-frail(n ¼ 111)

Frail(n ¼ 93)

P value (non/pre frail vs frail)

Re-Hospitalization(n,%)
Mortality(n,%)
Device Implant(n,%)
CVA(n,%)
Arrythmias(n,%)

0
1
1
0
1

7 (26.9)
3 (11.1)
11 (55)
2 (20)
13 (46.4)

19 (73.1)
23 (85.2)
9 (45)
8 (80)
14 (50)

0.006
0.001
0.857
0.061
0.760

(0)
(3.7)
(5)
(0)
(3.6)

was 60.59 ± 11.55 years with 15% patients aged less
than 50 years. Majority of patient populations consisted of farmers (34.1%) followed by retired/unemployed (26.2%). The male female ratio was 1.6:1.
Although most of the patients were in age group
50e75 years, there were 30 patients less than 50
years age who were either frail or pre-frail. Of all the
patients with heart failure enrolled in the study,
44.5% patients had coronary artery disease. The
mean left ventricular ejection fraction (LVEF) was
30.24 ± 6.8%. Majority of the patients were on diuretics (93.3%), however, only 42% patients were on
beta blockers and around three-fourth population
was on ACE-I/ARB.
The study population was further classiﬁed into
non-frail (2.8%), pre-frail (52.8%) and frail (44.2%)
according to the Fried frailty index (Table 1b).When
comparing the drug usage beta blocker and ACE I
usage was less in the frail population as compared
to the non-frail and pre-frail patients.
3.1. Study end-points
This study showed a signiﬁcant mortality in the
frail patient population as compared to the pre-frail/
non frail population (Table 2). Further, the rehospitalization rates till 12 months were higher in the
frail patients. The device implant rate for both the
populations was similar. Cerebrovascular events

were also higher in frail patients as compared to the
non-frail/pre-frail population. Documented arrhythmias were similar in both the groups. The
composite of heart failure related hospitalization
and mortality was signiﬁcantly higher in the frail
populations as compared to the other group. Kaplan
meir analysis showed a higher event free survival in
the non-frail or pre-frail population as compared to
the frail population at the end of one year (Fig. 2).
On univariate analysis, older age, frail patient, poor
hand grip, raised BNP were predictors for mortality.
It was also seen that the use of beta blockers and
ACE inhibitors prevented mortality. On multivariate analysis, frailty and poor hand grip could
identify the patients at increased risk of clinical
events (Table 3). On Cox regression analysis ACE I
and handgrip were inversely related to mortality.
Frailty was an independent predictor of mortality
(Hazard ratio 4.75, 95% CI 1.58 to 14.27, p Value 0.006). Handgrip strength was signiﬁcantly different
in the survivors and non-survivor group. The mean
handgrip strength in the survivors was 21.7 ± 7.6 kg
and 15.8 ± 5.5 kg in non-survivor group (p
value < 0.001). Predictive accuracy of handgrip
strength for prognosis is shown in the receiveroperating characteristic curve of hangrip strength to
predict survival in patients with CHF (Area under
the curve ¼ 0.75 with a p value¼<0.001) (Fig. 3).
Handgrip strength >16.95 kg had a sensitivity of

Fig. 2. Survival analysis for the a) Mortality, b) Event free survival.
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Table 3. a) Univariate analysis. Older age/poor handgrip/frailty and raised BNP were predictors of mortality and ACE inhibitors and beta-blockers
prevented mortality. (*p value < 0.05). b) Multivariate analysis: Frailty and handgrip strength can identify heart failure patients at increased risk.
Age
<50
50e75
>75
Sex
F
M
DRUGSBeta blockers
ACE I
Diuretics
Frailty type
Non-frail/Pre-Frail
Frail
Re-hospitalization
BMI(Kg/m) (Mean ± SD)
LVEF(%) (Mean ± SD)
Hemoglobin(gm/dl)(Mean ± SD)
BNP (Mean ± SD)
HAND GRIP(Mean ± SD)

Survival

Died

Chi-square value/Z

p-value

27 (14.8)
142 (77.6)
14 (7.7)

5 (18.5)
15 (55.6)
7 (25.9)

9.606

0.008

60 (32.8)
123 (67.2)

8 (29.6)
19 (70.4)

0.107

0.743

83 (45.4)
146 (79.8)
170 (92.9)

5 (18.5)
11 (40.7)
26 (96.3)

6.961
19.006
0.437

0.008
0.001
0.508

113 (61.7)
70 (38.3)
25 (13.7)
24.22 ± 1.81
29.94 ± 5.82
12.41 ± 1.81
792.12 ± 801.3
21.38 ± 6.61

4 (14.8)
23 (85.2)
1 (3.7)
23.58 ± 1.84
32.30 ± 11.37
11.07 ± 1.97
1575.47 ± 1061.2
16.41 ± 5.48

21.006

0.001

2.151
1.712
1.687
3.508
3.506
3.725

0.143
0.088
0.093
0.001
0.001
0.001

MULTIVARIATE ANALYSIS

AGE
ACE I
HANDGRIP
Frail

p-value

Exp(B)

95% C.I. for EXP(B)
Lower

Upper

0.780
0.004
0.016
0.003

0.994
0.252
0.889
5.835

0.953
0.100
0.807
1.799

1.037
0.637
0.978
18.928

4. Discussion

Fig. 3. Predictive accuracy of handgrip strength for prognosis is shown
in the receiver-operating characteristic curve of handgrip strength to
predict survival in patients with CHF (Area under the curve ¼ 0.75 with
a p value¼<0.001).

72% and speciﬁcity of 63% for the prediction of
survival in the patients with heart failure.

Frailty has been recognized as a potential target in
management of cardiovascular diseases and is seen
to be a dynamic condition which may be reversible
with appropriate interventions. To the best of our
knowledge this is the ﬁrst study in India evaluating
the outcome of frail population in heart failure patients with a simple bed-side/out-patient method.
This method of determination of frailty which may
be done by paramedical staff at rural areas and outpatient departments may be useful to identify the
high risk subset of patients which may improve
signiﬁcantly with measures aimed at frailty. Frailty
is a complex syndrome characterised by poor body
reserve with multiple organ systems involved and is
seen to occur increasingly with advancing age,
however, should not be considered synonymous
with ageing. We could see a striking presence of
frailty in younger age group patients with heart
failure. In our prospective study the left ventricular
ejection fraction did not differ in both the groups
(non frail/pre-frail versus frail). Similar to the heart
failure data from southern part of India from Trivandrum heart failure registry (THFR) [13], the
mean age of our population was 60.52 years.

However, ischemic heart disease as a cause of heart
failure in our population was seen in 44.5% as
compared to 72% population in the THFR. Our data
differs from the south Indian data as we included
patients with LVEF<40%. From previous studies
mortality at 5 years is seen to be around 50% from
the time of initial diagnosis [14]. Out of 93 frail patients in our study 23 (24.7%) died within one year,
which is higher mortality for patients on medical
therapy and constant supervision of physicians. One
of the important factor, is frailty which we found to
be associated with increased mortality rates in patients with heart failure. In our study 42% patients
were on beta blockers and 75% patients were on
ACE I/ARB. Thus guideline directed medical therapy could not be achieved in signiﬁcant number of
patients. This may be due to intolerance to beta
blockers or ACE I/ARB in our population. It has
been seen that elderly frail patients are less likely to
receive standard HF regimens [15] and frail HF patients beneﬁt more from an interdisciplinary
approach than non-frail HF patients [16]. In our
study the use of beta-blockers and ACEI/ARB was
associated with less mortality, and diuretics did not
prevent mortality. Raised BNP levels and anemia in
out-patients was also seen to associate with higher
mortality. Vidan et al. in the FRAIL HF study [17],
evaluated the relationships between the frailty
phenotype and associated issues (i.e. comorbidities,
coexistent geriatric syndromes, self-care and social
support) with clinical, functional and quality-of-life
outcomes in patients after heart failure hospitalization. The study found that even in non-dependent
patients, frailty was a risk factor for early disability,
long-term mortality and hospital readmission. As
compared to the data from western world, 40.6% of
the patients with heart failure we studied were frail.
The presence of frailty was associated with higher
mortality and hospitalization rates. In a recently
published meta-analysis by Yang et al. [18] frailty
had 1.5 fold hazard for death or hospitalization. In
our study the hazard for mortality or hospitalization
for frail patients with heart failure was 4.7 fold. This
may be in part due to lesser use of guideline recommended drugs, lower BMI of patients, compliance issues with drugs besides other factors like
anemia, dietery differences, monitoring and supervision of the patients. We could demonstrate that
poor handgrip and presence of frailty had a higher
risk of mortality and cardiovascular events in patients with heart failure. Handgrip strength measurement is a easy to use method which may be
used in peripheral centers and also in bed-ridden
patients. Although there are many frailty scales
available, but in a developing country like India
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with limited resources it is important to have simple
and practical method to apply on a large scale. This
method used in our study employs a hand held
dynamometer and a simple questionnaire which is
easy to use and may be used in other diseases also.
The pre-frail category of patients in this study had
lesser events as compared to the frail population,
which gives us an opportunity to intervene in this
group of patients to improve outcomes. Currently
frailty assessment is not done in all patients with
heart failure. This study highlights the impact of
frailty on clinical outcomes in heart failure patients
and encourages including frailty as a routine
assessment tool in all patients of heart failure.

5. Limitations
There are certain limitations to our study. It is a
single center non-randomized study. This is initial
study aimed to assess the utility of frailty measurement and effect of frailty on the outcomes. There
could have been a selections bias in our study as we
included the patients who came for hospital visits.
There are more number of patients who are unable
to visit hospitals due to various reasons; however,
this method may help identify the patients at primary health care level due to its ease of use. The
effect of intervention aimed at frailty needs to be
studied in a larger randomized multicenter trial.

6. Conclusion
Prevalence of frailty in heart failure is seen
commonly and may be present in younger age
group in Indian population. Presence of frailty increases the risk of mortality and rehospitalization.
Identiﬁcation of frailty may help to guide management (reduce mortality/improve quality of life)
which may be feasible at primary health care level
in a developing country with limited resources.This
study encourages to design a multinational study to
compare prevalence in different populations and
see effect of interventions.
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